Proteinuria

Researchers are testing whether a ketone supplement drink can reduce protein in the urine and improve kidney function in people with chronic kidney disease or polycystic kidney disease. The study includes 45 participants who receive either the ketone drink or a placebo for four w…

This study looked at whether taking kefir peptides for three months could help people with stage 3 or 4 chronic kidney disease. Researchers measured kidney function, protein in urine, and signs of inflammation. The goal was to see if this supplement could support disease control,…

This phase 2 trial tested whether adding the experimental drug lorundrostat to standard SGLT2 inhibitor therapy can lower blood pressure in adults with chronic kidney disease and albuminuria (protein in urine). Sixty participants received either lorundrostat or a placebo for four…

This study tested whether finerenone, a drug that blocks a hormone involved in kidney damage, can reduce protein in urine and slow kidney function decline. One hundred adults with non-diabetic glomerulonephritis took either finerenone or a placebo for 9 months, on top of their us…

This study looked at the long-term safety and effectiveness of a drug called pegunigalsidase alfa for adults with Fabry disease, a rare genetic condition. Participants received an infusion every four weeks for up to several years. The goal was to see if the drug is safe over time…

This study tested a new drug called VIS649 in 155 adults with IgA nephropathy, a kidney disease. The goal was to see if the drug is safe and can reduce protein in the urine, a sign of kidney damage. Participants received either the drug or a placebo, and researchers monitored sid…

This study looked at the long-term safety of pegunigalsidase alfa, an enzyme replacement therapy, in 97 adults with Fabry disease. Participants received the drug intravenously every two weeks for up to several years. The main goal was to track side effects and see how well the dr…

This study tested whether people with type 2 diabetes and kidney damage can safely participate in a clinical trial from home. Twelve participants took the drug empagliflozin, and depending on their response, some added or switched to finerenone. The goal was to see if remote data…

This phase 3 trial tested iptacopan (LNP023) in 518 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. Participants received either the drug or a placebo, on top of standard care. The goal was to see if iptacopan reduces protein in the urine and slows …

This study tested whether sodium phenylbutyrate, a drug already used for other conditions, can reduce a marker of kidney injury in people with proteinuric kidney disease. 26 participants took the drug for 14 days. The goal was to see a 50% drop in a urine marker called Lcn2, whic…

This completed trial tested a new drug called QRX-3 (Eseronate) in 45 people with chronic kidney disease stages 3-5. The goal was to see if the drug could slow the decline in kidney function and reduce protein in the urine. The study compared changes in kidney function over time.

This completed Phase 2 trial tested QRX-3, a drug that boosts NAD activity in kidney cells to reduce damage and improve function. 127 adults with chronic kidney disease stages 3-5 took part over 12 months. Researchers measured changes in kidney function and protein levels in urin…

This study looked at whether Huaier Granule, a traditional Chinese medicine, can reduce protein in the urine—a sign of kidney damage—caused by anti-angiogenesis targeted therapy in 76 adults with advanced liver or bile duct cancer. Participants took the granule for 8 weeks, and r…